BioSpace News Archive

RedHill Biopharma Ltd. announced that it has reached a non-binding agreement in principle with HCR Collateral Management, LLC with respect to the terms of a transfer of RedHill’s rights in Movantik® to HCR in exchange for the extinguishment of all RedHill’s obligations under the Credit Agreement between RedHill’s U.S. subsidiary RedHill Biopharma Inc. and HCR dated as of February 23, 2020.

ProKidney Corp. announced financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate developments.

Lumos Pharma, Inc. (NASDAQ:LUMO) today announced that interim results met expectations for its Phase 2 OraGrowtH210 Trial and Phase 2 Pharmacokinetic/Pharmacodynamic (PK/PD) OraGrowtH212 Trial evaluating oral LUM-201 for subjects with moderate (idiopathic) pediatric growth hormone deficiency (PGHD) who screened PEM-positive utilizing Lumos’s predictive enrichment marker (PEM) strategy.

Emergent BioSolutions Inc. announced a research award by the U.S. Department of Defense Congressionally Directed Medical Research Programs to evaluate efficacy of the company’s single-dose chikungunya virus virus-like particle vaccine candidate.

Xironetic (chiro-net-ik), an early-stage healthcare technology company, today announced its IntraOpVSP™ augmented reality (AR) visualization software for complex surgeries has received clearance from the U.S. Food and Drug Administration (FDA).

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced its financial results for the third quarter of 2022 and provided a business and clinical update.

Oxford, UK – 14November 2022: Oxford Biomedica plc, a leading gene and cell therapy group, announces exchange of contracts for the sale of its Windrush Court facility to Kadans Science Partner for £60 million.

OraSure Technologies, Inc. announced that Ken McGrath, Chief Financial Officer, will participate in a fireside chat at the Stephens Annual Investment Conference on November 17, 2022 at 9:00 am ET.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that updated clinical data from the ongoing IMMUNOCERV Phase 2 clinical trial was presented during a poster session on November 11 at the 37th Annual Meeting for the Society for Immunotherapy of Cancer (SITC 2022).

BioXcel Therapeutics, Inc. announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in fireside chats at two upcoming investor conferences.